Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.

Peroxisome proliferator-activated receptors (PPARs) compose a family of nuclear receptors that mediate the effects of lipidic ligands at the transcriptional level. In this review, we highlight advances in the understanding of the PPAR ligand binding domain (LBD) structure at the atomic level. The overall structure of PPARs LBD is described, and important protein ligand interactions are presented. Structure-activity relationships between isotypes structures and ligand specificity are addressed. It is shown that the numerous experimental three-dimensional structures available, together with in silico simulations, help understanding the role played by the activating function-2 (AF-2) in PPARs activation and its underlying molecular mechanism. The relation between the PPARs constitutive activity and the intrinsic stability of the active conformation is discussed. Finally, the interactions of PPARs LBD with co-activators or co-repressors, as well as with the retinoid X receptor (RXR) are described and considered in relation to PPARs activation.

[1]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R G Smith,et al.  Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.

[3]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[4]  W. Wahli,et al.  Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  R. Laskowski.  SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. , 1995, Journal of molecular graphics.

[6]  T. Kurtz,et al.  Design and Synthesis of the First Generation of Dithiolane Thiazolidinedione- and Phenylacetic Acid-Based PPARγ Agonists , 2006 .

[7]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[8]  W. Wahli,et al.  Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. , 2000, Molecular endocrinology.

[9]  J. Schwabe,et al.  A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.

[10]  Armin Ruf,et al.  A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .

[11]  Terry K. Smith,et al.  Reevaluation of the PPAR-β/δ Ligand Binding Domain Model Reveals Why It Exhibits the Activated Form , 2006 .

[12]  W. Wahli,et al.  Involvement of PPAR nuclear receptors in tissue injury and wound repair. , 2006, The Journal of clinical investigation.

[13]  J. Schwabe,et al.  Mechanism of the nuclear receptor molecular switch. , 2004, Trends in biochemical sciences.

[14]  S. Tuske,et al.  Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulators , 2006, Protein science : a publication of the Protein Society.

[15]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[16]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[17]  M. Lazar,et al.  A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis* , 2000, The Journal of Biological Chemistry.

[18]  Millard H. Lambert,et al.  Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα , 2002, Nature.

[19]  Jerry T. Thompson,et al.  Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays. , 2003, Bioorganic & medicinal chemistry.

[20]  Y. Chao,et al.  Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity , 2005 .

[21]  H. Xu,et al.  Structure-based design of potent retinoid X receptor alpha agonists. , 2004, Journal of medicinal chemistry.

[22]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[23]  I. Lu,et al.  Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. , 2006, Journal of medicinal chemistry.

[24]  L. Jendeberg,et al.  A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.

[25]  Béatrice Desvergne,et al.  From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. , 2006, Progress in lipid research.

[26]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[27]  R. Epple,et al.  1,3,5-Trisubstituted aryls as highly selective PPARδ agonists , 2006 .

[28]  K. Umesono,et al.  Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-α (PPARα) Generates a PPARδ Phenotype , 2000 .

[29]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[30]  P E Bourne,et al.  The Protein Data Bank. , 2002, Nucleic acids research.

[31]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[32]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[33]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Millard H. Lambert,et al.  Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .

[35]  Terry K. Smith,et al.  Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.

[36]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[37]  D. Higgins,et al.  T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.

[38]  W. Wahli,et al.  Be fit or be sick: peroxisome proliferator-activated receptors are down the road. , 2004, Molecular endocrinology.

[39]  Takayoshi Suzuki,et al.  Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2. , 2005, Bioorganic & medicinal chemistry letters.

[40]  Hans Peter Märki,et al.  Structure-based design of indole propionic acids as novel PPARα/γ co-agonists , 2006 .

[41]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[42]  T. Itoh,et al.  Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. , 2005, Bioorganic & medicinal chemistry letters.

[43]  Yong Li,et al.  Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Ingrid Pettersson,et al.  Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .

[45]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[46]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[47]  Ping-Chiang Lyu,et al.  Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. , 2006, Journal of medicinal chemistry.

[48]  C. Carlberg,et al.  Structural Determinants of the Agonist-independent Association of Human Peroxisome Proliferator-activated Receptors with Coactivators* , 2005, Journal of Biological Chemistry.

[49]  A. Burger,et al.  Regulation of the Transcriptional Activity of the Peroxisome Proliferator-activated Receptor α by Phosphorylation of a Ligand-independent trans-Activating Domain* , 1999, The Journal of Biological Chemistry.

[50]  Geoffrey J. Barton,et al.  The Jalview Java alignment editor , 2004, Bioinform..

[51]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[52]  W. Wahli,et al.  PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents , 1997, Biological chemistry.

[53]  J. Fleckner,et al.  Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.

[54]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[55]  Fulvio Loiodice,et al.  Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. , 2005, Journal of medicinal chemistry.